RxDoctor Payments DataLook up a doctor →

Chang Son, MD

Dermatology · Englewood, NJNPI 1063493898

Payments from drug & device makers

$76,575in general payments, 2019–2025

Across 415 payments — averaging $184.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$44K
  • Incyte Corporation$19K
  • E.r. Squibb & Sons, L.L.C.$6K
  • Merz North America, Inc.$3K
  • EPI Health, LLC$1K
  • Dermavant Sciences, Inc.$563
  • plus $3K from 31 others

What the payments were for

  • Consulting fees$2,9024%
  • Speaking & faculty fees$63,93683%
  • Travel & lodging$360%
  • Food & beverage$9,70013%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,575 in reported general payments places this provider in the 90th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$158,513
Medicare patients
364
Services billed
2,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast40$196,661
OpzeluraRuxolitinib Phosphate32$65,656
VtamaTapinarof20$27,713
ZoryveRoflumilast21$19,428
Tacrolimus95$17,249
Halobetasol Propionate247$15,168
Ketoconazole618$10,556
Clobetasol Propionate154$8,771
Fluocinonide164$7,443
Triamcinolone Acetonide654$5,717
Mupirocin316$4,108
Ivermectin12$3,893
Metronidazole48$3,863
Calcipotriene30$3,828
Clindamycin Phosphate122$3,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$43,722$196,66140 claims
Incyte CorporationOpzelura$18,771$65,65632 claims
Dermavant Sciences, Inc.Vtama$563$27,71320 claims
Arcutis Biotherapeutics, Inc.Zoryve$397$19,42821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →